Cefepime use: A need for antimicrobial stewardship

•Cefepime is a trendy subject due to its capacity to preserve carbapenems.•No study published on the use of cefepime until now.•One-year study of cefepime's proper use in a university hospital with implementation by an antimicrobial stewardship team.•Nine criteria were defined to accurately ana...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infectious diseases now (Online) 2021-08, Vol.51 (5), p.445-450
Hauptverfasser: Meurant, Alexandre, Guérin, François, Le Hello, Simon, Saint-Lorant, Guillaume, de La Blanchardière, Arnaud
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 450
container_issue 5
container_start_page 445
container_title Infectious diseases now (Online)
container_volume 51
creator Meurant, Alexandre
Guérin, François
Le Hello, Simon
Saint-Lorant, Guillaume
de La Blanchardière, Arnaud
description •Cefepime is a trendy subject due to its capacity to preserve carbapenems.•No study published on the use of cefepime until now.•One-year study of cefepime's proper use in a university hospital with implementation by an antimicrobial stewardship team.•Nine criteria were defined to accurately analyze how cefepime prescriptions can be improved.•In all, 13.4% of prescriptions met all criteria for proper use. Unlike other 3GCs, Cefepime is a cephalosporin that has, in animal model studies, shown a low risk of selecting resistant mutants. It also enables carbapenems to be saved in treatment of Pseudomonasaeruginosa and the CESP group (Citrobacter, Enterobacter, Serratia and Providencia, as well as the genus Klebsiellaaerogenes, Morganella and Hafnia), consequently producing cephalosporinase. We aimed to determine whether its prescription in a French teaching hospital met criteria for proper use. We conducted a retrospective study of proper cefepime use between March 1st, 2018 and February 28th, 2019, to assess indication, antimicrobial stewardship, dosing schedule, microbiological documentation, reevaluation, and treatment duration. Prescriptions were then compared to local guidelines established from international literature. Out of 142 cefepime prescriptions, 97.2% were prescribed as validated according to indication. The duration of the documented treatments matched the guidelines for 56.5% of patients, dosage was adapted to the indication for 77.4% and to kidney function for 97.2%. Bacteriological documentation was performed in all cases and an antibiogram was generated in 99.2% of cases. The treatment was reassessed between 48 and 72h and between the 7th and 10th day for 44.2% and 60.9% of the prescriptions respectively. The antimicrobial stewardship team managed half of the prescriptions. Only 13.4% of prescriptions met all criteria for proper use. Notwithstanding a highly sizable majority of validated indications, a very small proportion of cefepime prescriptions met all the criteria for proper use. In the context of increased cefepime consumption, which is favored by its increased place in the latest recommendations published in 2019, proper use of cefepime prescriptions needs to be more effectively promoted.
doi_str_mv 10.1016/j.idnow.2020.10.001
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04425298v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2666991920000019</els_id><sourcerecordid>2524361588</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-e97cb0c1e44f5be52442628fe385990b94a29798018a7dfb103d7e77620c46fb3</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMoWmqfQJBZ6qL15DKZieCiFG9QcKPrkMmcoSlzqcm04tubsVVcuUr4-c5_OB8hFxRmFKi8Wc9c2XYfMwZsSGYA9IiMmJRyqhRVx3_-Z2QSwhoAWEo5E_KUnHGuJHCgI8IWWOHGNZhsA94m86RFLJOq84lpe9c467vCmToJPX4YX4aV25yTk8rUASeHd0zeHu5fF0_T5cvj82K-nFrB836KKrMFWIpCVGmBKROCSZZXyPNUKSiUMExlKgeam6ysCgq8zDDLJAMrZFXwMbne965MrTfeNcZ_6s44_TRf6iGD2Jgyle9oZK_27MZ371sMvW5csFjXpsVuG3TkBJc0zfOI8j0aTwvBY_XbTUEPbvVaf7vVg9shjG7j1OVhwbZosPyd-TEZgbs9gFHJzqHXwTpsLZbOo-112bl_F3wBCLiIOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2524361588</pqid></control><display><type>article</type><title>Cefepime use: A need for antimicrobial stewardship</title><source>Alma/SFX Local Collection</source><creator>Meurant, Alexandre ; Guérin, François ; Le Hello, Simon ; Saint-Lorant, Guillaume ; de La Blanchardière, Arnaud</creator><creatorcontrib>Meurant, Alexandre ; Guérin, François ; Le Hello, Simon ; Saint-Lorant, Guillaume ; de La Blanchardière, Arnaud</creatorcontrib><description>•Cefepime is a trendy subject due to its capacity to preserve carbapenems.•No study published on the use of cefepime until now.•One-year study of cefepime's proper use in a university hospital with implementation by an antimicrobial stewardship team.•Nine criteria were defined to accurately analyze how cefepime prescriptions can be improved.•In all, 13.4% of prescriptions met all criteria for proper use. Unlike other 3GCs, Cefepime is a cephalosporin that has, in animal model studies, shown a low risk of selecting resistant mutants. It also enables carbapenems to be saved in treatment of Pseudomonasaeruginosa and the CESP group (Citrobacter, Enterobacter, Serratia and Providencia, as well as the genus Klebsiellaaerogenes, Morganella and Hafnia), consequently producing cephalosporinase. We aimed to determine whether its prescription in a French teaching hospital met criteria for proper use. We conducted a retrospective study of proper cefepime use between March 1st, 2018 and February 28th, 2019, to assess indication, antimicrobial stewardship, dosing schedule, microbiological documentation, reevaluation, and treatment duration. Prescriptions were then compared to local guidelines established from international literature. Out of 142 cefepime prescriptions, 97.2% were prescribed as validated according to indication. The duration of the documented treatments matched the guidelines for 56.5% of patients, dosage was adapted to the indication for 77.4% and to kidney function for 97.2%. Bacteriological documentation was performed in all cases and an antibiogram was generated in 99.2% of cases. The treatment was reassessed between 48 and 72h and between the 7th and 10th day for 44.2% and 60.9% of the prescriptions respectively. The antimicrobial stewardship team managed half of the prescriptions. Only 13.4% of prescriptions met all criteria for proper use. Notwithstanding a highly sizable majority of validated indications, a very small proportion of cefepime prescriptions met all the criteria for proper use. In the context of increased cefepime consumption, which is favored by its increased place in the latest recommendations published in 2019, proper use of cefepime prescriptions needs to be more effectively promoted.</description><identifier>ISSN: 2666-9919</identifier><identifier>EISSN: 2666-9919</identifier><identifier>DOI: 10.1016/j.idnow.2020.10.001</identifier><identifier>PMID: 33960301</identifier><language>eng</language><publisher>Elsevier Masson SAS</publisher><subject>Antimicrobial stewardship ; Cefepime ; Cephalosporinase ; Drug resistance ; Enterobacteriaceae ; Life Sciences ; Pharmaceutical sciences</subject><ispartof>Infectious diseases now (Online), 2021-08, Vol.51 (5), p.445-450</ispartof><rights>2020 Elsevier Masson SAS</rights><rights>Copyright © 2020 Elsevier Masson SAS. All rights reserved.</rights><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-e97cb0c1e44f5be52442628fe385990b94a29798018a7dfb103d7e77620c46fb3</citedby><cites>FETCH-LOGICAL-c438t-e97cb0c1e44f5be52442628fe385990b94a29798018a7dfb103d7e77620c46fb3</cites><orcidid>0000-0001-6821-3131</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33960301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://normandie-univ.hal.science/hal-04425298$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Meurant, Alexandre</creatorcontrib><creatorcontrib>Guérin, François</creatorcontrib><creatorcontrib>Le Hello, Simon</creatorcontrib><creatorcontrib>Saint-Lorant, Guillaume</creatorcontrib><creatorcontrib>de La Blanchardière, Arnaud</creatorcontrib><title>Cefepime use: A need for antimicrobial stewardship</title><title>Infectious diseases now (Online)</title><addtitle>Infect Dis Now</addtitle><description>•Cefepime is a trendy subject due to its capacity to preserve carbapenems.•No study published on the use of cefepime until now.•One-year study of cefepime's proper use in a university hospital with implementation by an antimicrobial stewardship team.•Nine criteria were defined to accurately analyze how cefepime prescriptions can be improved.•In all, 13.4% of prescriptions met all criteria for proper use. Unlike other 3GCs, Cefepime is a cephalosporin that has, in animal model studies, shown a low risk of selecting resistant mutants. It also enables carbapenems to be saved in treatment of Pseudomonasaeruginosa and the CESP group (Citrobacter, Enterobacter, Serratia and Providencia, as well as the genus Klebsiellaaerogenes, Morganella and Hafnia), consequently producing cephalosporinase. We aimed to determine whether its prescription in a French teaching hospital met criteria for proper use. We conducted a retrospective study of proper cefepime use between March 1st, 2018 and February 28th, 2019, to assess indication, antimicrobial stewardship, dosing schedule, microbiological documentation, reevaluation, and treatment duration. Prescriptions were then compared to local guidelines established from international literature. Out of 142 cefepime prescriptions, 97.2% were prescribed as validated according to indication. The duration of the documented treatments matched the guidelines for 56.5% of patients, dosage was adapted to the indication for 77.4% and to kidney function for 97.2%. Bacteriological documentation was performed in all cases and an antibiogram was generated in 99.2% of cases. The treatment was reassessed between 48 and 72h and between the 7th and 10th day for 44.2% and 60.9% of the prescriptions respectively. The antimicrobial stewardship team managed half of the prescriptions. Only 13.4% of prescriptions met all criteria for proper use. Notwithstanding a highly sizable majority of validated indications, a very small proportion of cefepime prescriptions met all the criteria for proper use. In the context of increased cefepime consumption, which is favored by its increased place in the latest recommendations published in 2019, proper use of cefepime prescriptions needs to be more effectively promoted.</description><subject>Antimicrobial stewardship</subject><subject>Cefepime</subject><subject>Cephalosporinase</subject><subject>Drug resistance</subject><subject>Enterobacteriaceae</subject><subject>Life Sciences</subject><subject>Pharmaceutical sciences</subject><issn>2666-9919</issn><issn>2666-9919</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKAzEUhoMoWmqfQJBZ6qL15DKZieCiFG9QcKPrkMmcoSlzqcm04tubsVVcuUr4-c5_OB8hFxRmFKi8Wc9c2XYfMwZsSGYA9IiMmJRyqhRVx3_-Z2QSwhoAWEo5E_KUnHGuJHCgI8IWWOHGNZhsA94m86RFLJOq84lpe9c467vCmToJPX4YX4aV25yTk8rUASeHd0zeHu5fF0_T5cvj82K-nFrB836KKrMFWIpCVGmBKROCSZZXyPNUKSiUMExlKgeam6ysCgq8zDDLJAMrZFXwMbne965MrTfeNcZ_6s44_TRf6iGD2Jgyle9oZK_27MZ371sMvW5csFjXpsVuG3TkBJc0zfOI8j0aTwvBY_XbTUEPbvVaf7vVg9shjG7j1OVhwbZosPyd-TEZgbs9gFHJzqHXwTpsLZbOo-112bl_F3wBCLiIOA</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Meurant, Alexandre</creator><creator>Guérin, François</creator><creator>Le Hello, Simon</creator><creator>Saint-Lorant, Guillaume</creator><creator>de La Blanchardière, Arnaud</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0001-6821-3131</orcidid></search><sort><creationdate>20210801</creationdate><title>Cefepime use: A need for antimicrobial stewardship</title><author>Meurant, Alexandre ; Guérin, François ; Le Hello, Simon ; Saint-Lorant, Guillaume ; de La Blanchardière, Arnaud</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-e97cb0c1e44f5be52442628fe385990b94a29798018a7dfb103d7e77620c46fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antimicrobial stewardship</topic><topic>Cefepime</topic><topic>Cephalosporinase</topic><topic>Drug resistance</topic><topic>Enterobacteriaceae</topic><topic>Life Sciences</topic><topic>Pharmaceutical sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meurant, Alexandre</creatorcontrib><creatorcontrib>Guérin, François</creatorcontrib><creatorcontrib>Le Hello, Simon</creatorcontrib><creatorcontrib>Saint-Lorant, Guillaume</creatorcontrib><creatorcontrib>de La Blanchardière, Arnaud</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Infectious diseases now (Online)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meurant, Alexandre</au><au>Guérin, François</au><au>Le Hello, Simon</au><au>Saint-Lorant, Guillaume</au><au>de La Blanchardière, Arnaud</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cefepime use: A need for antimicrobial stewardship</atitle><jtitle>Infectious diseases now (Online)</jtitle><addtitle>Infect Dis Now</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>51</volume><issue>5</issue><spage>445</spage><epage>450</epage><pages>445-450</pages><issn>2666-9919</issn><eissn>2666-9919</eissn><abstract>•Cefepime is a trendy subject due to its capacity to preserve carbapenems.•No study published on the use of cefepime until now.•One-year study of cefepime's proper use in a university hospital with implementation by an antimicrobial stewardship team.•Nine criteria were defined to accurately analyze how cefepime prescriptions can be improved.•In all, 13.4% of prescriptions met all criteria for proper use. Unlike other 3GCs, Cefepime is a cephalosporin that has, in animal model studies, shown a low risk of selecting resistant mutants. It also enables carbapenems to be saved in treatment of Pseudomonasaeruginosa and the CESP group (Citrobacter, Enterobacter, Serratia and Providencia, as well as the genus Klebsiellaaerogenes, Morganella and Hafnia), consequently producing cephalosporinase. We aimed to determine whether its prescription in a French teaching hospital met criteria for proper use. We conducted a retrospective study of proper cefepime use between March 1st, 2018 and February 28th, 2019, to assess indication, antimicrobial stewardship, dosing schedule, microbiological documentation, reevaluation, and treatment duration. Prescriptions were then compared to local guidelines established from international literature. Out of 142 cefepime prescriptions, 97.2% were prescribed as validated according to indication. The duration of the documented treatments matched the guidelines for 56.5% of patients, dosage was adapted to the indication for 77.4% and to kidney function for 97.2%. Bacteriological documentation was performed in all cases and an antibiogram was generated in 99.2% of cases. The treatment was reassessed between 48 and 72h and between the 7th and 10th day for 44.2% and 60.9% of the prescriptions respectively. The antimicrobial stewardship team managed half of the prescriptions. Only 13.4% of prescriptions met all criteria for proper use. Notwithstanding a highly sizable majority of validated indications, a very small proportion of cefepime prescriptions met all the criteria for proper use. In the context of increased cefepime consumption, which is favored by its increased place in the latest recommendations published in 2019, proper use of cefepime prescriptions needs to be more effectively promoted.</abstract><pub>Elsevier Masson SAS</pub><pmid>33960301</pmid><doi>10.1016/j.idnow.2020.10.001</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-6821-3131</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2666-9919
ispartof Infectious diseases now (Online), 2021-08, Vol.51 (5), p.445-450
issn 2666-9919
2666-9919
language eng
recordid cdi_hal_primary_oai_HAL_hal_04425298v1
source Alma/SFX Local Collection
subjects Antimicrobial stewardship
Cefepime
Cephalosporinase
Drug resistance
Enterobacteriaceae
Life Sciences
Pharmaceutical sciences
title Cefepime use: A need for antimicrobial stewardship
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T22%3A15%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cefepime%20use:%20A%20need%20for%20antimicrobial%20stewardship&rft.jtitle=Infectious%20diseases%20now%20(Online)&rft.au=Meurant,%20Alexandre&rft.date=2021-08-01&rft.volume=51&rft.issue=5&rft.spage=445&rft.epage=450&rft.pages=445-450&rft.issn=2666-9919&rft.eissn=2666-9919&rft_id=info:doi/10.1016/j.idnow.2020.10.001&rft_dat=%3Cproquest_hal_p%3E2524361588%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2524361588&rft_id=info:pmid/33960301&rft_els_id=S2666991920000019&rfr_iscdi=true